NIIMBL Unveils 3 Vaccine Manufacturing Projects Valued at $1.7M
The Executive Headlines
“The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced around $1.7M in planned project activities via the Global Health Fund of the Institute Project Call6.1G for three new projects.”
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced around $1.7M in planned project activities via the Global Health Fund of the Institute Project Call6.1G for three new projects.
These three projects have been designed to develop in vitro potency assays for vaccines being produced by viral vector technologies or mRNA vector technologies.
With keeping the key focus areas in the vision of NIIMBL and the Bill and Melinda Gates Foundation (BMGF), these projects were chosen to address industry needs.
NIIMBL established the Global Health Fund with funding offered by the Bill and Melinda Gates Foundation to develop and execute innovative technologies for biological and vaccine manufacturing that will speed up development timelines and reduce the cost of manufacturing, all in the extension of BMGF’s charitable objectives.
Chris Roberts, Associate Institute Director, said, “NIIMBL is looking forward to adding these key projects to our GHF portfolio. These projects will allow us to further advance innovation in vaccine manufacturing, particularly around potency assays that are important for the characterization of key quality aspects of vaccines. The recent pandemic highlighted several needs for vaccine development and manufacturing across multiple potential vaccine targets. These projects will make significant advances for vaccine manufacturing”.
NIIMBL has awarded 142 technical, and Global Health Fund projects via the Project Call procedure with an overall project investment of more than $111M since 2017 when NIIMBL was established.
The NIIMBL community includes over 200 members from industry, academia, non-profit organizations, and government agencies. Each of them shares a common objective of advancing pharmaceutical manufacturing.